Nuclear Medicine and Radiopharmaceutic-Global Market Status and Trend Report 2013-2023
Report Summary
Nuclear Medicine and Radiopharmaceutic-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Nuclear Medicine and Radiopharmaceutic industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Nuclear Medicine and Radiopharmaceutic 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Nuclear Medicine and Radiopharmaceutic worldwide, with company and product introduction, position in the Nuclear Medicine and Radiopharmaceutic market
Market status and development trend of Nuclear Medicine and Radiopharmaceutic by types and applications
Cost and profit status of Nuclear Medicine and Radiopharmaceutic, and marketing status
Market growth drivers and challenges
The report segments the global Nuclear Medicine and Radiopharmaceutic market as:
Global Nuclear Medicine and Radiopharmaceutic Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Nuclear Medicine and Radiopharmaceutic Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Diagnostic Radioisotopes
Therapeutic Radioisotopes
Global Nuclear Medicine and Radiopharmaceutic Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Oncology
Cardiology
Others
Global Nuclear Medicine and Radiopharmaceutic Market: Manufacturers Segment Analysis (Company and Product introduction, Nuclear Medicine and Radiopharmaceutic Sales Volume, Revenue, Price and Gross Margin):
Company
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Nuclear Medicine and Radiopharmaceutic-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Nuclear Medicine and Radiopharmaceutic industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Nuclear Medicine and Radiopharmaceutic 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Nuclear Medicine and Radiopharmaceutic worldwide, with company and product introduction, position in the Nuclear Medicine and Radiopharmaceutic market
Market status and development trend of Nuclear Medicine and Radiopharmaceutic by types and applications
Cost and profit status of Nuclear Medicine and Radiopharmaceutic, and marketing status
Market growth drivers and challenges
The report segments the global Nuclear Medicine and Radiopharmaceutic market as:
Global Nuclear Medicine and Radiopharmaceutic Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Nuclear Medicine and Radiopharmaceutic Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Diagnostic Radioisotopes
Therapeutic Radioisotopes
Global Nuclear Medicine and Radiopharmaceutic Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Oncology
Cardiology
Others
Global Nuclear Medicine and Radiopharmaceutic Market: Manufacturers Segment Analysis (Company and Product introduction, Nuclear Medicine and Radiopharmaceutic Sales Volume, Revenue, Price and Gross Margin):
Company
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF NUCLEAR MEDICINE AND RADIOPHARMACEUTIC
1.1 Definition of Nuclear Medicine and Radiopharmaceutic in This Report
1.2 Commercial Types of Nuclear Medicine and Radiopharmaceutic
1.2.1 Diagnostic Radioisotopes
1.2.2 Therapeutic Radioisotopes
1.3 Downstream Application of Nuclear Medicine and Radiopharmaceutic
1.3.1 Oncology
1.3.2 Cardiology
1.3.3 Others
1.4 Development History of Nuclear Medicine and Radiopharmaceutic
1.5 Market Status and Trend of Nuclear Medicine and Radiopharmaceutic 2013-2023
1.5.1 Global Nuclear Medicine and Radiopharmaceutic Market Status and Trend 2013-2023
1.5.2 Regional Nuclear Medicine and Radiopharmaceutic Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Nuclear Medicine and Radiopharmaceutic 2013-2017
2.2 Sales Market of Nuclear Medicine and Radiopharmaceutic by Regions
2.2.1 Sales Volume of Nuclear Medicine and Radiopharmaceutic by Regions
2.2.2 Sales Value of Nuclear Medicine and Radiopharmaceutic by Regions
2.3 Production Market of Nuclear Medicine and Radiopharmaceutic by Regions
2.4 Global Market Forecast of Nuclear Medicine and Radiopharmaceutic 2018-2023
2.4.1 Global Market Forecast of Nuclear Medicine and Radiopharmaceutic 2018-2023
2.4.2 Market Forecast of Nuclear Medicine and Radiopharmaceutic by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Nuclear Medicine and Radiopharmaceutic by Types
3.2 Sales Value of Nuclear Medicine and Radiopharmaceutic by Types
3.3 Market Forecast of Nuclear Medicine and Radiopharmaceutic by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Nuclear Medicine and Radiopharmaceutic by Downstream Industry
4.2 Global Market Forecast of Nuclear Medicine and Radiopharmaceutic by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Nuclear Medicine and Radiopharmaceutic Market Status by Countries
5.1.1 North America Nuclear Medicine and Radiopharmaceutic Sales by Countries (2013-2017)
5.1.2 North America Nuclear Medicine and Radiopharmaceutic Revenue by Countries (2013-2017)
5.1.3 United States Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
5.1.4 Canada Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
5.1.5 Mexico Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
5.2 North America Nuclear Medicine and Radiopharmaceutic Market Status by Manufacturers
5.3 North America Nuclear Medicine and Radiopharmaceutic Market Status by Type (2013-2017)
5.3.1 North America Nuclear Medicine and Radiopharmaceutic Sales by Type (2013-2017)
5.3.2 North America Nuclear Medicine and Radiopharmaceutic Revenue by Type (2013-2017)
5.4 North America Nuclear Medicine and Radiopharmaceutic Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Nuclear Medicine and Radiopharmaceutic Market Status by Countries
6.1.1 Europe Nuclear Medicine and Radiopharmaceutic Sales by Countries (2013-2017)
6.1.2 Europe Nuclear Medicine and Radiopharmaceutic Revenue by Countries (2013-2017)
6.1.3 Germany Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.1.4 UK Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.1.5 France Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.1.6 Italy Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.1.7 Russia Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.1.8 Spain Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.1.9 Benelux Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.2 Europe Nuclear Medicine and Radiopharmaceutic Market Status by Manufacturers
6.3 Europe Nuclear Medicine and Radiopharmaceutic Market Status by Type (2013-2017)
6.3.1 Europe Nuclear Medicine and Radiopharmaceutic Sales by Type (2013-2017)
6.3.2 Europe Nuclear Medicine and Radiopharmaceutic Revenue by Type (2013-2017)
6.4 Europe Nuclear Medicine and Radiopharmaceutic Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Nuclear Medicine and Radiopharmaceutic Market Status by Countries
7.1.1 Asia Pacific Nuclear Medicine and Radiopharmaceutic Sales by Countries (2013-2017)
7.1.2 Asia Pacific Nuclear Medicine and Radiopharmaceutic Revenue by Countries (2013-2017)
7.1.3 China Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
7.1.4 Japan Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
7.1.5 India Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
7.1.6 Southeast Asia Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
7.1.7 Australia Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
7.2 Asia Pacific Nuclear Medicine and Radiopharmaceutic Market Status by Manufacturers
7.3 Asia Pacific Nuclear Medicine and Radiopharmaceutic Market Status by Type (2013-2017)
7.3.1 Asia Pacific Nuclear Medicine and Radiopharmaceutic Sales by Type (2013-2017)
7.3.2 Asia Pacific Nuclear Medicine and Radiopharmaceutic Revenue by Type (2013-2017)
7.4 Asia Pacific Nuclear Medicine and Radiopharmaceutic Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Nuclear Medicine and Radiopharmaceutic Market Status by Countries
8.1.1 Latin America Nuclear Medicine and Radiopharmaceutic Sales by Countries (2013-2017)
8.1.2 Latin America Nuclear Medicine and Radiopharmaceutic Revenue by Countries (2013-2017)
8.1.3 Brazil Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
8.1.4 Argentina Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
8.1.5 Colombia Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
8.2 Latin America Nuclear Medicine and Radiopharmaceutic Market Status by Manufacturers
8.3 Latin America Nuclear Medicine and Radiopharmaceutic Market Status by Type (2013-2017)
8.3.1 Latin America Nuclear Medicine and Radiopharmaceutic Sales by Type (2013-2017)
8.3.2 Latin America Nuclear Medicine and Radiopharmaceutic Revenue by Type (2013-2017)
8.4 Latin America Nuclear Medicine and Radiopharmaceutic Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Market Status by Countries
9.1.1 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Revenue by Countries (2013-2017)
9.1.3 Middle East Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
9.1.4 Africa Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
9.2 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Market Status by Manufacturers
9.3 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Sales by Type (2013-2017)
9.3.2 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Revenue by Type (2013-2017)
9.4 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF NUCLEAR MEDICINE AND RADIOPHARMACEUTIC
10.1 Global Economy Situation and Trend Overview
10.2 Nuclear Medicine and Radiopharmaceutic Downstream Industry Situation and Trend Overview
CHAPTER 11 NUCLEAR MEDICINE AND RADIOPHARMACEUTIC MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Nuclear Medicine and Radiopharmaceutic by Major Manufacturers
11.2 Production Value of Nuclear Medicine and Radiopharmaceutic by Major Manufacturers
11.3 Basic Information of Nuclear Medicine and Radiopharmaceutic by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Nuclear Medicine and Radiopharmaceutic Major Manufacturer
11.3.2 Employees and Revenue Level of Nuclear Medicine and Radiopharmaceutic Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 NUCLEAR MEDICINE AND RADIOPHARMACEUTIC MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Company
12.1.1 Company profile
12.1.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.1.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Company
12.2 Bracco Imaging
12.2.1 Company profile
12.2.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.2.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Bracco Imaging
12.3 Bayer
12.3.1 Company profile
12.3.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.3.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Bayer
12.4 Mallinckrodt
12.4.1 Company profile
12.4.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.4.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Mallinckrodt
12.5 Nordion
12.5.1 Company profile
12.5.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.5.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Nordion
12.6 Triad Isotopes
12.6.1 Company profile
12.6.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.6.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Triad Isotopes
12.7 Lantheus
12.7.1 Company profile
12.7.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.7.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Lantheus
12.8 IBA Group
12.8.1 Company profile
12.8.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.8.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of IBA Group
12.9 GE Healthcare
12.9.1 Company profile
12.9.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.9.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of GE Healthcare
12.10 China Isotope & Radiation
12.10.1 Company profile
12.10.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.10.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of China Isotope & Radiation
12.11 Jubilant Pharma
12.11.1 Company profile
12.11.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.11.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Jubilant Pharma
12.12 Eli Lilly
12.12.1 Company profile
12.12.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.12.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Eli Lilly
12.13 Advanced Accelerator Applications
12.13.1 Company profile
12.13.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.13.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Advanced Accelerator Applications
12.14 SIEMENS
12.14.1 Company profile
12.14.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.14.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of SIEMENS
12.15 Dongcheng
12.15.1 Company profile
12.15.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.15.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Dongcheng
12.16 Navidea
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NUCLEAR MEDICINE AND RADIOPHARMACEUTIC
13.1 Industry Chain of Nuclear Medicine and Radiopharmaceutic
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF NUCLEAR MEDICINE AND RADIOPHARMACEUTIC
14.1 Cost Structure Analysis of Nuclear Medicine and Radiopharmaceutic
14.2 Raw Materials Cost Analysis of Nuclear Medicine and Radiopharmaceutic
14.3 Labor Cost Analysis of Nuclear Medicine and Radiopharmaceutic
14.4 Manufacturing Expenses Analysis of Nuclear Medicine and Radiopharmaceutic
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Nuclear Medicine and Radiopharmaceutic in This Report
1.2 Commercial Types of Nuclear Medicine and Radiopharmaceutic
1.2.1 Diagnostic Radioisotopes
1.2.2 Therapeutic Radioisotopes
1.3 Downstream Application of Nuclear Medicine and Radiopharmaceutic
1.3.1 Oncology
1.3.2 Cardiology
1.3.3 Others
1.4 Development History of Nuclear Medicine and Radiopharmaceutic
1.5 Market Status and Trend of Nuclear Medicine and Radiopharmaceutic 2013-2023
1.5.1 Global Nuclear Medicine and Radiopharmaceutic Market Status and Trend 2013-2023
1.5.2 Regional Nuclear Medicine and Radiopharmaceutic Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Nuclear Medicine and Radiopharmaceutic 2013-2017
2.2 Sales Market of Nuclear Medicine and Radiopharmaceutic by Regions
2.2.1 Sales Volume of Nuclear Medicine and Radiopharmaceutic by Regions
2.2.2 Sales Value of Nuclear Medicine and Radiopharmaceutic by Regions
2.3 Production Market of Nuclear Medicine and Radiopharmaceutic by Regions
2.4 Global Market Forecast of Nuclear Medicine and Radiopharmaceutic 2018-2023
2.4.1 Global Market Forecast of Nuclear Medicine and Radiopharmaceutic 2018-2023
2.4.2 Market Forecast of Nuclear Medicine and Radiopharmaceutic by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Nuclear Medicine and Radiopharmaceutic by Types
3.2 Sales Value of Nuclear Medicine and Radiopharmaceutic by Types
3.3 Market Forecast of Nuclear Medicine and Radiopharmaceutic by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Nuclear Medicine and Radiopharmaceutic by Downstream Industry
4.2 Global Market Forecast of Nuclear Medicine and Radiopharmaceutic by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Nuclear Medicine and Radiopharmaceutic Market Status by Countries
5.1.1 North America Nuclear Medicine and Radiopharmaceutic Sales by Countries (2013-2017)
5.1.2 North America Nuclear Medicine and Radiopharmaceutic Revenue by Countries (2013-2017)
5.1.3 United States Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
5.1.4 Canada Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
5.1.5 Mexico Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
5.2 North America Nuclear Medicine and Radiopharmaceutic Market Status by Manufacturers
5.3 North America Nuclear Medicine and Radiopharmaceutic Market Status by Type (2013-2017)
5.3.1 North America Nuclear Medicine and Radiopharmaceutic Sales by Type (2013-2017)
5.3.2 North America Nuclear Medicine and Radiopharmaceutic Revenue by Type (2013-2017)
5.4 North America Nuclear Medicine and Radiopharmaceutic Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Nuclear Medicine and Radiopharmaceutic Market Status by Countries
6.1.1 Europe Nuclear Medicine and Radiopharmaceutic Sales by Countries (2013-2017)
6.1.2 Europe Nuclear Medicine and Radiopharmaceutic Revenue by Countries (2013-2017)
6.1.3 Germany Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.1.4 UK Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.1.5 France Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.1.6 Italy Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.1.7 Russia Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.1.8 Spain Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.1.9 Benelux Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
6.2 Europe Nuclear Medicine and Radiopharmaceutic Market Status by Manufacturers
6.3 Europe Nuclear Medicine and Radiopharmaceutic Market Status by Type (2013-2017)
6.3.1 Europe Nuclear Medicine and Radiopharmaceutic Sales by Type (2013-2017)
6.3.2 Europe Nuclear Medicine and Radiopharmaceutic Revenue by Type (2013-2017)
6.4 Europe Nuclear Medicine and Radiopharmaceutic Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Nuclear Medicine and Radiopharmaceutic Market Status by Countries
7.1.1 Asia Pacific Nuclear Medicine and Radiopharmaceutic Sales by Countries (2013-2017)
7.1.2 Asia Pacific Nuclear Medicine and Radiopharmaceutic Revenue by Countries (2013-2017)
7.1.3 China Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
7.1.4 Japan Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
7.1.5 India Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
7.1.6 Southeast Asia Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
7.1.7 Australia Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
7.2 Asia Pacific Nuclear Medicine and Radiopharmaceutic Market Status by Manufacturers
7.3 Asia Pacific Nuclear Medicine and Radiopharmaceutic Market Status by Type (2013-2017)
7.3.1 Asia Pacific Nuclear Medicine and Radiopharmaceutic Sales by Type (2013-2017)
7.3.2 Asia Pacific Nuclear Medicine and Radiopharmaceutic Revenue by Type (2013-2017)
7.4 Asia Pacific Nuclear Medicine and Radiopharmaceutic Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Nuclear Medicine and Radiopharmaceutic Market Status by Countries
8.1.1 Latin America Nuclear Medicine and Radiopharmaceutic Sales by Countries (2013-2017)
8.1.2 Latin America Nuclear Medicine and Radiopharmaceutic Revenue by Countries (2013-2017)
8.1.3 Brazil Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
8.1.4 Argentina Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
8.1.5 Colombia Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
8.2 Latin America Nuclear Medicine and Radiopharmaceutic Market Status by Manufacturers
8.3 Latin America Nuclear Medicine and Radiopharmaceutic Market Status by Type (2013-2017)
8.3.1 Latin America Nuclear Medicine and Radiopharmaceutic Sales by Type (2013-2017)
8.3.2 Latin America Nuclear Medicine and Radiopharmaceutic Revenue by Type (2013-2017)
8.4 Latin America Nuclear Medicine and Radiopharmaceutic Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Market Status by Countries
9.1.1 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Revenue by Countries (2013-2017)
9.1.3 Middle East Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
9.1.4 Africa Nuclear Medicine and Radiopharmaceutic Market Status (2013-2017)
9.2 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Market Status by Manufacturers
9.3 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Sales by Type (2013-2017)
9.3.2 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Revenue by Type (2013-2017)
9.4 Middle East and Africa Nuclear Medicine and Radiopharmaceutic Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF NUCLEAR MEDICINE AND RADIOPHARMACEUTIC
10.1 Global Economy Situation and Trend Overview
10.2 Nuclear Medicine and Radiopharmaceutic Downstream Industry Situation and Trend Overview
CHAPTER 11 NUCLEAR MEDICINE AND RADIOPHARMACEUTIC MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Nuclear Medicine and Radiopharmaceutic by Major Manufacturers
11.2 Production Value of Nuclear Medicine and Radiopharmaceutic by Major Manufacturers
11.3 Basic Information of Nuclear Medicine and Radiopharmaceutic by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Nuclear Medicine and Radiopharmaceutic Major Manufacturer
11.3.2 Employees and Revenue Level of Nuclear Medicine and Radiopharmaceutic Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 NUCLEAR MEDICINE AND RADIOPHARMACEUTIC MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Company
12.1.1 Company profile
12.1.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.1.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Company
12.2 Bracco Imaging
12.2.1 Company profile
12.2.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.2.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Bracco Imaging
12.3 Bayer
12.3.1 Company profile
12.3.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.3.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Bayer
12.4 Mallinckrodt
12.4.1 Company profile
12.4.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.4.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Mallinckrodt
12.5 Nordion
12.5.1 Company profile
12.5.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.5.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Nordion
12.6 Triad Isotopes
12.6.1 Company profile
12.6.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.6.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Triad Isotopes
12.7 Lantheus
12.7.1 Company profile
12.7.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.7.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Lantheus
12.8 IBA Group
12.8.1 Company profile
12.8.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.8.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of IBA Group
12.9 GE Healthcare
12.9.1 Company profile
12.9.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.9.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of GE Healthcare
12.10 China Isotope & Radiation
12.10.1 Company profile
12.10.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.10.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of China Isotope & Radiation
12.11 Jubilant Pharma
12.11.1 Company profile
12.11.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.11.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Jubilant Pharma
12.12 Eli Lilly
12.12.1 Company profile
12.12.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.12.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Eli Lilly
12.13 Advanced Accelerator Applications
12.13.1 Company profile
12.13.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.13.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Advanced Accelerator Applications
12.14 SIEMENS
12.14.1 Company profile
12.14.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.14.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of SIEMENS
12.15 Dongcheng
12.15.1 Company profile
12.15.2 Representative Nuclear Medicine and Radiopharmaceutic Product
12.15.3 Nuclear Medicine and Radiopharmaceutic Sales, Revenue, Price and Gross Margin of Dongcheng
12.16 Navidea
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NUCLEAR MEDICINE AND RADIOPHARMACEUTIC
13.1 Industry Chain of Nuclear Medicine and Radiopharmaceutic
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF NUCLEAR MEDICINE AND RADIOPHARMACEUTIC
14.1 Cost Structure Analysis of Nuclear Medicine and Radiopharmaceutic
14.2 Raw Materials Cost Analysis of Nuclear Medicine and Radiopharmaceutic
14.3 Labor Cost Analysis of Nuclear Medicine and Radiopharmaceutic
14.4 Manufacturing Expenses Analysis of Nuclear Medicine and Radiopharmaceutic
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
